KCL researchers identify key features of autoimmune diseases present in the gut
Globally affecting 4% of the population, autoimmune diseases mistakenly attack healthy cells, tissues and organs in the body
Read More
Tag: Lupus
US study reveals interferon combinations cause lupus symptoms and affect treatment
The autoimmune disease, which affects 1.5 million people in the US, causes the body’s immune system to attack its own tissues
Read More
Strategic collaboration strengthens lupus clinical research in UK
There is currently no cure for lupus, and many of the existing therapies have shown varying degrees of success
Read More
EC clears GSK’s Benlysta for lupus nephritis
The drug is the only biologic treatment approved in Europe that is specifically designed to work in systemic lupus erythematosus and lupus nephritis
Read More
GlaxoSmithKline wins Benlysta US label expansion for children
The approval marks the first medicine in the US approved for children with systemic lupus erythematosus.
Read More
Immugenyx and Janssen to develop humanised mouse model of lupus
UK biopharma Hemogenyx Pharmaceuticals has signed a deal with Janssen Research & Development to create a humanised mouse model of lupus.
Read More
Mixed data for Xencor’s SLE drug
Xencor’s experimental systemic lupus erythematosus (SLE) drug XmAb5871 has failed to hit its key target in a mid-stage study.
Read More
AZ’ lupus therapy fails to hit the mark
AstraZeneca’s experimental drug anifrolumab has failed to hit targets in a late stage trial in patients with lupus.
Read More
Lilly to progress Olumiant into PhIII for lupus
The Lancet has published full results of a Phase II trial showing the benefit of Lilly’s JAK inhibitor Olumiant in the treatment of global systemic lupus erythematosus (SLE).
Read More
Ablynx’ vobarilizumab fails in lupus trial
Ablynx’ vobarilizumab has failed to hit targets in a mid-stage trial assessing its safety and effectiveness as a treatment for systemic lupus erythematosus (SLE).
Read More
GSK trials Benlysta/rituximab combo for lupus
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
Read More
EU approves subcutaneous form of GSK’s Benlysta
A new subcutaneous formulation of GlaxoSmithKline’s Benlysta has been approved as an add-on therapy for certain in adults with the autoimmune disease systemic lupus erythematosus (SLE).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
